Firms Should Look To Local CROs For Clinical Trials in Asia
This article was originally published in The Pink Sheet Daily
Executive Summary
Asia medical consultant highlights advantages of China and India.
You may also be interested in...
Indian Pharma Focusing On R&D, Licensing – Ranbaxy Exec
Indian firms are flush with cash and looking to move from generic drugs to proprietary compounds, Ranbaxy’s Shyam Bishen tells “The Pink Sheet” DAILY.
Novartis Shanghai R&D Center To Focus On Diseases Prevalent In China
Establishment of the R&D site reflects Novartis’ commitment to the region, according to the drug maker.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: